Clinical Trial Results: Myelogenous Leukemia, Chronic

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: II
A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: To be Published
Phase: III
Expanded Access Program A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Product Name: PEGASYS [peginterferon alfa-2a (40KD)]
Date of Report: 4/1/2008
Phase: III
Phase II Randomized Multicenter Comparative Study of Peginterferon alfa-2a vs. Roferon-A for the Treatment of Patients with Recently Diagnosed Chronic Phase Myelogenous Leukemia (CML) not Previously Treated with Interferon.